Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer

Journal of Immunotherapy

Volumn 35, Issue 6, 2012, Pages 513-521

  Fujiwara, Shinichi ^a   Wada, Hisashi ^a   Miyata, Hiroshi ^a   Kawada, Junji ^a   Kawabata, Ryohei ^a   Nishikawa, Hiroyoshi ^a   Gnjatic, Sacha ^b   Sedrak, Christine ^b   Sato, Eiichi ^c   Nakamura, Yurika ^a   Sakakibara, Mitsuru ^d   Kanto, Tatsuya ^d   Shimosegawa, Eku ^e   Hatazawa, Jun ^e   Takahashi, Tsuyoshi ^a   Kurokawa, Yukinori ^a   Yamasaki, Makoto ^a   Nakajima, Kiyokazu ^a   Takiguchi, Shuji ^a   Nakayama, Eiichi ^f   Mori, Masaki ^a   Doki, Yuichiro ^a   more..

^a OSAKA UNIVERSITY   (Japan)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d Department of Gastroenterology and Hepatology ^*  (Japan)

^e GRADUATE SCHOOL OF MEDICINE   (Japan)

^f KAWASAKI UNIVERSITY OF MEDICAL WELFARE   (Japan)

Author keywords

antibody against 28 tumor antigens; CD83 + cells; chemoimmunotherapy; DC migration; DTH; esophageal cancer; intratumoral DC administration; KLH; NY ESO 1 specific T cell response; scintigraphy

Indexed keywords

CD83 ANTIGEN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; INDIUM 111; KEYHOLE LIMPET HEMOCYANIN;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL MIGRATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; LYMPH NODE; MALE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SKIN TEST;

ANTIGENS, CD38; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INDIUM; MEMBRANE PROTEINS; RADIOIMMUNOTHERAPY;

EID: 84864196063     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182619cb4     Document Type: Article

References (30)

1. Makino T, Yamasaki M, Takeno A, et al. Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus. Br J Cancer. 2009;101:1298-1306.
2. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004;53:925-930. (Pubitemid 38824146)
3. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086-1092.
4. Yasunaga M, Tabira Y, Nakano K, et al. Accelerated growth signals and low tumor-infiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma. Ann Thorac Surg. 2000;70:1634-1640.
5. Tsujitani S, Saito H, Oka S, et al. Significance of RCAS1 antigen in hepatocellular, cholangiocellular and pancreatic carcinomas. Dig Dis. 2007;52:549-554.
6. Yang W, Yu J. Immunologic function of dendritic cells in esophageal cancer. Dig Dis Sci. 2008;53:1739-1746.
7. Liu Q, Hao C, Su P, et al. Down-regulation of HLA class I antigen-processing machinery components in esophageal squamous cell carcinomas: association with disease progression. Scand J Gastroenterol. 2009;44:960-969.
8. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 1997;94:1914-1918. (Pubitemid 27113936)
9. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006;95:1-30. (Pubitemid 44088423)
10. Aymeric L, Apetoh L, Ghiringhelli F, et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res. 2010;70:855-858.
11. Yang D, Chen Q, Yang H, et al. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol. 2007;81:59-66. (Pubitemid 46021253)
12. Mazzolini G, Alfaro C, Sangro B, et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol. 2005;23:999-1010. (Pubitemid 46202319)
13. Mann DL, Celluzzi CM, Hankey KG, et al. Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers. Ann N Y Acad Sci. 2009;1174:41-50.
14. Sakakibara M, Kanto T, Inoue M, et al. Quick generation of fully mature dendritic cells from monocytes with OK432, lowdose prostanoid, and interferon-alpha as potent immune enhancers. J Immunother. 2006;29:67-77.
15. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of The Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655. (Pubitemid 13149996)
16. Japan Esophageal Society. Japanese Classification of Esophageal Cancer, 10th edition: Part II and III. Esophagus. 2009;6:71-94.
17. Barth RJ Jr, Fisher DA, Wallace PK, et al. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res. 2010;16: 5548-5556.
18. Gnjatic S, Ritter E, Bü chler MW, et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci USA. 2010;107:5088-5093.
19. Kawada J, Wada H, Isobe M, et al. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. Int J Cancer. 2012;130: 584-592.
20. De Vries IJ, Krooshoop DJ, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003;63:12-17. (Pubitemid 36070411)
21. Tanaka F, Yamaguchi H, Ohta M, et al. Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo. Int J Cancer. 2002;101: 265-269. (Pubitemid 34970895)
22. Ridolfi R, Riccobon A, Galassi R, et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med. 2004;2:27.
23. Quillien V, Moisan A, Carsin A, et al. Biodistribution of radiolabelled human dendritic cells injected by various routes. Eur J Nucl Med Mol Imaging. 2005;32:731-741. (Pubitemid 41125414)
24. Vincent J, Mignot G, Chalmin F, et al. 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70:3052-3061.
25. Zhao J, Cao Y, Lei Z, et al. Selective depletion of CD4+ CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res. 2010;70:4850-4858.
26. Spanos WC, Nowicki P, Lee DW, et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009;135:1137-1146.
27. Shimakawa T, Naritaka Y, Asaka S, et al. Neoadjuvant chemotherapy (FAP) for advanced esophageal cancer. Anticancer Res. 2008;28:2321-2326.
28. Drutman SB, Trombetta ES. Dendritic cells continue to capture and present antigens after maturation in vivo. J Immunol. 2010; 185:2140-2146.
29. Palucka AK, Ueno H, Fay JW, et al. Taming cancer by inducing immunity via dendritic cells. Immunol Rev. 2007;220:129-150. (Pubitemid 350045575)
30. Lubaroff DM, Karan D. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer. Adv Drug Deliv Rev. 2009;61:268-274.